Research Update: Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Patients With Transverse Myelitis
A Phase I study called, “Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis” is currently enrolling participants. The study, nicknamed The Q-Cell Study, is sponsored by the University of Texas Southwestern, Q Therapeutics, Inc., and the Siegel Rare Neuroimmune Association (SRNA). You can learn more about the study on the clinical trial site here and on SRNA’s website here.
The Q-Cell study is the first FDA-approved study to test if the implantation of cells can repair spinal cord damage in individuals diagnosed with transverse myelitis. During the study, the Q-cells will be surgically implanted into each participant’s spinal cord at the level of a lesion.
To date, two patients have been enrolled in the study. Investigators are now screening and enrolling up to seven additional participants for the study. Potential participants must be non-ambulatory adults diagnosed with transverse myelitis. The study is being conducted at The University of Texas Southwestern Medical Center in Dallas, TX, so participants will need to be able to travel to that location in order to undergo surgery.
